96 Tests PN: A111131

32 Tests PN: A111131T

Components:

45x Ab-conjugated beads  (S5P10 - Human IL-10 ab-bead).

  • 96 Tests PN: A111131A. One vial containing 100 µL of anti-human IL-10 conjugated to AimPlex Bead S5P10.

  • 32 Tests PN: A111131TA. One vial containing 35 µL of anti-human IL-10 conjugated to AimPlex Bead S5P10.

25x Biotin-detection Ab (Human IL-10 Biotin-dAb).

  • 96 Tests PN: A111131B. One vial containing 100 µL of biotinylated anti-human IL-10.

  • 32 Tests PN: A111131TB. One vial containing 35 µL of biotinylated anti-human IL-10.

Lyophilized Standard Mix-Human Group 1 Panel A, 7-Plex.

  • 96 & 32 Tests PN: HG10007. One vial containing lyophilized recombinant IFNγ, IL-2, IL-4, IL-6, IL-10, IL-17A, and TNFα. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits

Application: Optimal antibody pair and antigen standard for assaying human IL-10.  Can be multiplexed with other analytes in Human Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (96 Tests PN: P100001, 32 Tests PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 2pg/mL

  • Quantitation range:

  • LLOQ: < 5 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 1: Negligible

  • Sample volume: 15 µL/test

Description:

Interleukin-10 (IL-10)/cytokine synthesis inhibitory factor (CSIF) (Accession P22301) is a member of the Interleukin-10 subfamily and class 2 cytokine. IL-10 is predominantly expressed by monocytes and to a smaller degree, lymphocytes.In mice, IL-10 has also been shown to be produced in mast cells. IL-10 acts as an anti-inflammatory cytokine by downregulating expression of Th1 and NK cells and macrophages. It enhances B-cell proliferation and antibody production and inhibits LPS and bacteria induction into proinflammatory cytokines such as IFN-γ, IL-12, and IL-1β. IL-10 is often expressed with pro-inflammatory cytokines, though the necessary pathways may negatively impact the function of the other cytokines. IL-10 has been shown to have links to melanoma, multiple sclerosis, and vascular and cardiac dysfunction in mice.

References:

  1. Couper KN, Blount DG, Riley EM. IL-10: The Master Regulator of Immunity to Infection. J Immunol. 2008; 180(9) 5771-5777. Doi: 10.4049.jimmunol.180.9.5771.

  2. Grimbaldston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nature Immunology. 2007; 8(10): 1095-104. Doi:10.1038/ni1503.

  3. Opp MR, Smith EM, Huges TK. Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rates to reduce sleep. Journal of Neuroimmunology. 1995; 60(1-2): 165-8. Doi:10.1016/0165-5728(95)00066.

  4. Sikka G, Miller KL, Steppan J, Pandey D, Jung SM, Fraser CD, Ellis C, Ross D, Vandegaer K, Bedja D, Gabrielson K, Walston JD, Berkowitz DE, Barouch LA. Interleukin 10 knowckout frail mice develop cardiac and vascular dysfunction with increased age. Experimental Gerontology. 2013; 48(2): 128-35. Doi: 10.1016/j.exger.2012.11.001.

  5. Varma TK, Toliver-Kinsky TE, Lin CY, Koutrouvelis AP, Nichols JE, Sherwood ER. Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice. Infection and Immunity. 2001; 69(9): 5249-63. Doi: 10.1128/iai.69.9.5249-5263.2001.